9.83
3.69%
0.35
Dopo l'orario di chiusura:
10.00
0.17
+1.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Precedente Chiudi:
$9.48
Aprire:
$9.51
Volume 24 ore:
78,813
Relative Volume:
0.86
Capitalizzazione di mercato:
$30.36M
Reddito:
$7.97M
Utile/perdita netta:
$-75.74M
Rapporto P/E:
-5.1466
EPS:
-1.91
Flusso di cassa netto:
$-85.33M
1 W Prestazione:
+5.02%
1M Prestazione:
+20.47%
6M Prestazione:
-51.46%
1 anno Prestazione:
-48.28%
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Nome
Aligos Therapeutics Inc
Settore
Industria
Telefono
(800) 466-6059
Indirizzo
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
2023-01-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2022-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
2022-01-07 | Downgrade | JP Morgan | Overweight → Neutral |
2022-01-06 | Downgrade | Jefferies | Buy → Hold |
2021-09-09 | Iniziato | SVB Leerink | Outperform |
2021-05-17 | Ripresa | Piper Sandler | Overweight |
2020-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
2020-11-10 | Iniziato | JP Morgan | Overweight |
2020-11-10 | Iniziato | Jefferies | Buy |
2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 - StockTitan
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% – Here’s What Happened - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 5.4%Here's What Happened - MarketBeat
HC Wainwright Reiterates Buy Rating for Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Aligos Therapeutics' (ALGS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 - The Manila Times
Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH) - 2 Minute Medicine
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap UpWhat's Next? - MarketBeat
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 202 - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 8.4%Should You Sell? - MarketBeat
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Increase in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Trading 4.9% HigherStill a Buy? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges By Investing.com - Investing.com South Africa
Aligos Therapeutics (NASDAQ:ALGS) Hits New 1-Year LowWhat's Next? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges - Investing.com Australia
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos TherapeuticsIt's All About Chronic Hepatitis B - RTTNews
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 6.2%Should You Sell? - MarketBeat
Aligos Therapeutics appoints new VP of Business Development By Investing.com - Investing.com Australia
Aligos Therapeutics appoints new VP of Business Development - Investing.com
Aligos Therapeutics Appoints David Perry as Vice President of Business Development - The Manila Times
Aligos Therapeutics to Present at Investor Conferences in October - The Manila Times
(ALGS) Investment Analysis and Advice - Stock Traders Daily
Aligos Therapeutics keeps stock target, overweight rating on promising data By Investing.com - Investing.com Australia
Aligos Therapeutics names new chief medical officer By Investing.com - Investing.com Australia
Aligos Therapeutics keeps stock target, overweight rating on promising data - Investing.com
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aligos Therapeutics names new chief medical officer - Investing.com
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer - StockTitan
Aligos Therapeutics stock hits 52-week low at $8.5 - Investing.com
Aligos Therapeutics stock hits 52-week low at $8.5 By Investing.com - Investing.com Canada
Aligos Therapeutics (NASDAQ:ALGS) Sets New 52-Week Low at $8.28 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Reaches New 52-Week Low at $8.28 - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16 - Defense World
Aligos Therapeutics' (ALGS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $10.18 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright - Defense World
Market Recap Check: Aligos Therapeutics Inc (ALGS)’s Negative Finish at 10.18, Up/Down -28.11 - The Dwinnex
Aligos Phase II results for ALG-055009 in MASH fail to impress - The Pharma Letter
Aligos shares maintain Buy rating with price target after study - Investing.com
Aligos reports positive data from Phase IIa MASH treatment trial - Clinical Trials Arena
Aligos reports progress in MASH treatment study - Investing.com
Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):